KCT0005368
Not yet recruiting
未知
Efficacy and safety of Hominis placenta pharmacopuncture on mild cognitive impairment: Randomized, Double blind, Placebo-controlled, Multi-center Trial
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Kyung Hee University
- Enrollment
- 30
- Status
- Not yet recruiting
- Last Updated
- 5 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\) Male or female adult aged 50 to 80\.
- •2\) A person diagnosed with mild neurocognitive impairment based on DSM\-5\.
- •3\) A person who can undergo neuropsychological tests and complete questionnaires.
- •4\) A person who agrees to participate in the trial after receiving explanations regarding the purpose and procedures involved in the clinical trial and has signed the informed consent form by oneself or one’s legal representative.
- •5\) A person with a score of 0\.5 on the CDR.
Exclusion Criteria
- •1\) A person with a cranial lesion or brain injury that can cause cognitive decline.
- •2\) A person with a history of cerebral hemorrhage or cerebral infarction.
- •3\) A person with brain diseases such as Parkinson’s disease, epilepsy, and brain cancer.
- •4\) A person with a present illness or past history of a major psychiatric disorder such as schizophrenia, delusional disorder, depressive disorder, bipolar disorder, or alcohol or substance abuse disorder as diagnosed using DSM\-5\.
- •5\) A person who has participated in other clinical trials within the last one month.
- •6\) A person who had acupuncture treatment for cognitive impairment within the last four weeks.
- •7\) A person who is currently taking medication related to dementia (If the person is diagnosed with MCI and is taking dementia\-related drugs, he/she may participate in the clinical trial after the wash\-out period of 15 days).
- •8\) A person with a severely destabilizing general medical condition (a doctor in charge will judge the enrollment based on the results of laboratory tests, vital signs, etc.).
- •9\) A person with a clinically serious liver disease or with serum aspartate transaminase and alanine transaminase levels exceeding twice the upper limit of reference value.
- •10\) A person with chronic renal failure or with serum blood urea nitrogen and creatinine levels exceeding 1\.5 times the upper limit of reference value.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Phase 2
Safety and efficacy of exosome Injection in perianal fistulaIRCT20211212053361N1Tehran University of Medical Sciences15
Not yet recruiting
Not Applicable
Effectiveness of placenta mesenchymal stem cell-derived exosomes on embryo implantation rate in women with recurrent implantation failureRecurrent Implantation Failure.Complication associated with artificial fertilization, unspecifiedN98.9IRCT20130812014333N223Kermanshah University of Medical Sciences15
Recruiting
Phase 1
human placenta in the treatment of skin wrinklesskin wrinkles.Other specified disorders of the skin and subcutaneous tissueL98.8IRCT20210612051545N3Tehran University of Medical Sciences20
Not yet recruiting
Not Applicable
Is there any benefit of using a topical gel prepared from human body to improve wound healing after laser gum lightening procedure?Health Condition 1: K137- Other and unspecified lesions of oral mucosaCTRI/2022/07/043850Dr Shubhankar Mehrotra
Completed
Not Applicable
Hominis Placenta Pharmacopuncture for treating insomnia disorderKCT0005127Pusan National University Korean Medicine Hospital51